ABSTRACT:
Biomedical science is experiencing an industrial revolution whereby paradigm shift on New Approach Methodologies (NAMs) focusing on in silico models, in vitro systems and organ-on-chip technologies are replacing traditional animal testing. This shift is a revolutionary step of changing the way research and innovation will be performed based on being more ethical, efficient, and human-relevant in its scientific practices. The paper examines how this transition has been transformed into regulatory frameworks across the United States, European Union and India where the three regions are central to the development of global biomedical research standards. It critically assesses the progress of regulation, the problem of implementation, the process of scientific validation and the current attempts to harmonize and standardize NAMs internationally. Notwithstanding recent developments, adopting and assimilating these new approaches is challenging. The absence of consistent regulatory expectations, variations in validation methods, disparities in data interpretation, and the lack of infrastructure to support the process in the various locations are the main obstacles. Furthermore, it is quite probable that converting NAM-generated data into outcomes that are acceptable by traditional regulatory frameworks would lead to ambiguity and inadequate acceptability. Governments, academic institutions, business, and regulatory bodies must collaborate to promote openness, reciprocal acknowledgment, and shared scientific knowledge in order to address these issues. Effective NAM implementation and worldwide biomedical innovation standardization ultimately depend on the development of strong institutional frameworks and ongoing policy resources.